Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A potential link between increase in total cholesterol and triglycerides and clinical improvement has been observed during antipsychotic drug treatment in chronic schizophrenia patients, possibly due to drug related effects on lipid biosynthesis. We examined whether changes in serum lipids are associated with alleviation of psychosis symptoms after one year of antipsychotic drug treatment in a cohort of first-episode psychosis (FEP) patients. METHODS: A total of 132 non-affective antipsychotic-treated FEP patients were included through the Norwegian Thematically Organized Psychosis (TOP) project. Data on antipsychotic usage, serum lipids (total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides (TG)), body mass index (BMI) and clinical state were obtained at baseline and after 12months. The Positive and Negative Syndrome Scale (PANSS) was used to assess psychotic symptoms. Mixed-effects models were employed to examine the relationship between serum lipids and psychotic symptoms while controlling for potential confounders including BMI. RESULTS: An increase in HDL during one year of antipsychotic treatment was associated with reduction in PANSS negative subscores (B=-0.48, p=0.03). This relationship was not affected by concurrent change in BMI (adjusted HDL: B=-0.54, p=0.02). No significant associations were found between serum lipids, BMI and PANSS positive subscores. CONCLUSION: We found that an increase in HDL level during antipsychotic treatment is associated with improvement in negative symptoms in FEP. These findings warrant further investigation to clarify the interaction between lipid pathways and psychosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597 · cited 1×
“…studies that report a positive link between treatment-related weight gain and improvement in psychosis (Bai et al., 2006; Czobor et al., 2002; Gupta et al., 1999; Hermes et al., 2011; Lamberti et al., 1992; Lane et al., 2003; Leadbetter et al., 1992; Meltzer et al., 2003; Sharma et al., 2014).”
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Dietschy, J. M., & Turley, S. D. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400004-jlr200 · Cited by 1,095 · cited 1×
“, 2015) also indicate an involvement of lipids, as cholesterol is crucial for myelin formation and functioning (Dietschy and Turley, 2004; Saher et al., 2005; Verheijen et al., 2003).”
High cholesterol level is essential for myelin membrane growth
Saher, G., Brügger, B., Lappe-Siefke, C., Möbius, W., Tozawa, R.-I., Wehr, M. C., Wieland, F., Ishibashi, S., & Nave, K.-A. (2005) · Nature Neuroscience · doi:10.1038/nn1426 · Cited by 799 · cited 2×
“The extent of alcohol use was measured with The Alcohol Use Disorders Identification Test (AUDIT) (Saunders et al., 1993).”
InfluentialWhite Matter Changes in Schizophrenia: Evidence for Myelin-Related Dysfunction
Davis, K. L., Stewart, D. G., Friedman, J. I., Buchsbaum, M., Harvey, P. D., Hof, P. R., Buxbaum, J., & Haroutunian, V. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.5.443 · Cited by 793
Reliability and validity of a depression rating scale for schizophrenics
Addington, D., Addington, J., Maticka-Tyndale, E., & Joyce, J. (1992) · Schizophrenia Research · doi:10.1016/0920-9964(92)90003-n · Cited by 651 · cited 2×
“Depression was assessed with the Calgary Depression Scale for Schizophrenia (CDSS) (Addington et al., 1992).”
Andreassen, O. A., Djurovic, S., Thompson, W. K., Schork, A. J., Kendler, K. S., O’Donovan, M. C., Rujescu, D., Werge, T., van de Bunt, M., Morris, A. P., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.01.001 · Cited by 506
Self-citationCorrell, C. U., Robinson, D. G., Schooler, N. R., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., Marcy, P., Addington, J., Estroff, S. E., Robinson, J., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1314 · Cited by 384
Xu, H. (2010) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2010.00008 · Cited by 108
Impaired Plasmalogens in Patients with Schizophrenia
Kaddurah-Daouk, R., McEvoy, J., Baillie, R., Zhu, H., K. Yao, J., Nimgaonkar, V. L., Buckley, P. F., Keshavan, M. S., Georgiades, A., & Nasrallah, H. A. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.02.019 · Cited by 89 · cited 2×
“Recent advances in lipidomics research, moreover, have linked changes in cell membrane lipid profiles to treatment response, signifying the multifaceted role of lipids in psychosis (Kaddurah-Daouk et al., 2012; Tessier et al., 2016).”
Cited by
Morris, G., Puri, B. K., Bortolasci, C. C., Carvalho, A., Berk, M., Walder, K., Moreira, E. G., & Maes, M. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.037 · Cited by 84
Monocyte/HDL Cholesterol Ratios as a New Inflammatory Marker in Patients with Schizophrenia
Kılıç, N., Tasci, G., Yılmaz, S., Öner, P., & Korkmaz, S. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020276 · Cited by 15
“It was reported that the increased serum HDL-C levels with the use of antipsychotics that did not cause weight gain for one year after the first episode of psychosis reduced negative symptoms [28].”
BackgroundEditorial: Brain-Metabolic Crossroads in Severe Mental Disorders—Focus on Metabolic Syndrome
Salvi, V., & Hajek, T. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00492 · Cited by 11
“Besides insulin, other mediators such as total and HDL cholesterol levels play key roles in the brain and were found to have pathoplastic effects on psychiatric disorders: the former has been repeatedly associated with suicide risk (5), the latter with higher prevalence of negative symptoms in schizophrenia (6).”
Background
Metadata
- Authors
- Gjerde, P. B., Dieset, I., Simonsen, C., Hoseth, E. Z., Iversen, T., Lagerberg, T. V., Lyngstad, S. H., Mørch, R. H., Skrede, S., Andreassen, O. A., Melle, I., & Steen, V. M.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 197
- Pages
- 253-260
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2767566448
- Cited by
- 40
- References
- 11
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.